Clinical significance of sHER2 ‑ECD and calpain‑10 expression in tumor tissues of patients with breast cancer.

In conclusion, sHER2‑ECD and tissue calpain‑10 may be used as new prognostic indices for breast cancer. PMID: 32236617 [PubMed - as supplied by publisher]
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research

Related Links:

Conclusions: Our report is the first study to examine the distant metastatic breast cancer proteome using FFPE tissues. The depth of our dataset allowed us to discover a novel biomarker candidate and a proteomic characteristics of distant metastatic breast cancer. Distinct molecular features of various breast cancer subtypes were also established. Our proteomic data constitute a valuable resource for research on distant metastatic breast cancer. PMID: 32489334 [PubMed]
Source: Clinical Genitourinary Cancer - Category: Cancer & Oncology Authors: Tags: Clin Proteomics Source Type: research
Conclusions: In the present study, the most recent and largest administrative database analysis of a Canadian population to date, we observed a subtype distribution consistent with previously reported data, together with comparable annual incidence and overall survival patterns. PMID: 32489268 [PubMed - in process]
Source: Current Oncology - Category: Cancer & Oncology Tags: Curr Oncol Source Type: research
In conclusion, we designed specific and sensitive methods to detect LALBA transcripts. We show for the first time a differential expression of these transcripts, but we need to confirm their potential use as markers in breast cancer. PMID: 32464003 [PubMed - indexed for MEDLINE]
Source: Journal of Environmental Pathology, Toxicology and Oncology - Category: Environmental Health Tags: J Environ Pathol Toxicol Oncol Source Type: research
Tucatinib in combination with trastuzumab and capecitabine yielded significant intracranial responses in patients with previously treated HER2-positive metastatic breast cancer and brain metastases.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
Source: Cancer Management and Research - Category: Cancer & Oncology Tags: Cancer Management and Research Source Type: research
Authors: Gomes I, de Almeida BP, Dâmaso S, Mansinho A, Correia I, Henriques S, Cruz-Duarte R, Vilhais G, Félix P, Alves P, Corredeira P, Barbosa-Morais NL, Costa L, Casimiro S Abstract The role of RANKL-RANK pathway in progesterone-driven mammary carcinogenesis and triple negative breast cancer tumorigenesis has been well characterized. However, and despite evidences of the existence of RANK-positive hormone receptor (HR)-positive breast tumors, the implication of RANK expression in HR-positive breast cancers has not been addressed before. Here, we report that RANK pathway affects the expression of cel...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
British Journal of Cancer, Published online: 03 June 2020; doi:10.1038/s41416-020-0909-4Phase 2 study of cabazitaxel as second-line treatment in patients with HER2-negative metastatic breast cancer previously treated with taxanes—a Hellenic Cooperative Oncology Group (HeCOG) Trial
Source: British Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research
HER2 is a transmembrane tyrosine kinase receptor, belonging to the epidermal growth factor receptor (EGFR) family, which is overexpressed in less than 20% of breast cancers [1]; as early as 1986, HER2 was established as a strong negative prognostic marker [2]. The monoclonal antibody trastuzumab was the first targeted agent specifically designed for the treatment of HER2-positive BC. Trastuzumab is directed against the extracellular domain of HER2 leading to the inhibition of the receptor, and blockade of the autophosphorylation cascade, and cell degradation via immunological effects.
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Systematic or Meta-analysis Studies Source Type: research
Cancers, Vol. 12, Pages 1453: DSCAM-AS1-Driven Proliferation of Breast Cancer Cells Involves Regulation of Alternative Exon Splicing and 3′-End Usage Cancers doi: 10.3390/cancers12061453 Authors: Jamal Elhasnaoui Valentina Miano Giulio Ferrero Elena Doria Antonette E. Leon Aline S. C. Fabricio Laura Annaratone Isabella Castellano Anna Sapino Michele De Bortoli DSCAM-AS1 is a cancer-related long noncoding RNA with higher expression levels in Luminal A, B, and HER2-positive Breast Carcinoma (BC), where its expression is strongly dependent on Estrogen Receptor Alpha (ERα). DSCAM-AS1 e...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
AbstractPrevious studies reported heterogeneous associations between obesity and reproductive-related breast cancer risk factors and breast cancer intrinsic subtypes; however, few studies have been conducted in Asian populations. Here, we aimed to examine whether risks associated with established breast cancer risk factors varied by breast cancer subtypes in Chinese women. We conducted a hospital-based case-control study in Hong Kong, including a total of 2169 Chinese women. Unconditional polytomous logistic regression models were used to calculate adjusted odds ratios (AORs) and 95% confidence intervals(95%CIs) to estimat...
Source: Hormones and Cancer - Category: Cancer & Oncology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | HER2